PRDX4

Across TCGA pan-cancer cohorts, PRDX4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PRDX4 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PRDX4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PRDX4 expression acts as an unfavorable survival marker.

CCRCC, PDAC, and GBM are the cancer types where PRDX4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.605	1.000	.001	33	view →
PDAC	DFS	Tertile	III,IV	0.382	0.810	.004	20	view →
GBM	OS	Median	All	0.248	0.527	<.001	18	view →
LUAD	OS	Median	II,III,IV	0.869	0.993	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PRDX4–CCRCC (OS)

Open the CCRCC breakdown →